<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393808</url>
  </required_header>
  <id_info>
    <org_study_id>PROCEED</org_study_id>
    <secondary_id>2011-001713-14</secondary_id>
    <nct_id>NCT01393808</nct_id>
  </id_info>
  <brief_title>Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes</brief_title>
  <acronym>PROCEED</acronym>
  <official_title>A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proteinuria is an independent risk factor for cardiovascular morbidity and mortality and for&#xD;
      renal disease progression. More proteinuria is associated with faster progression, whereas&#xD;
      treatments that reduce proteinuria are renoprotective in both diabetic and non diabetic&#xD;
      chronic kidney disease. Of note, lower the residual proteinuria achieved by treatment slower&#xD;
      is the disease progression in the long term. On the basis of the above findings, proteinuria&#xD;
      has become a target of renoprotective therapy.&#xD;
&#xD;
      Among different antihypertensive medications, those that inhibit the Renin Angiotensin&#xD;
      System, such as angiotensin converting enzyme (ACE)inhibitors and angiotensin receptor&#xD;
      blockers (ARBs), are those that at comparable blood pressure control, more effectively reduce&#xD;
      proteinuria and slow renal disease progression. Thus they have become the key component of&#xD;
      renoprotective therapy in patients with proteinuric chronic kidney disease. Observational&#xD;
      studies found that their effectiveness, however, is limited or even fully blunted in patients&#xD;
      who eat large amount of salt.&#xD;
&#xD;
      Experimental evidence indicates a renoprotective role of the vitamin D system in chronic&#xD;
      renal disease. A recent randomized, controlled trial, add-on therapy with selective Vitamin D&#xD;
      receptor activator paricalcitol showed an additive antiproteinuric effect in subjects with&#xD;
      type 2 diabetes and chronic kidney disease on background Renin-angiotensin-system inhibitor&#xD;
      therapy. This effect, however, was largely restricted to subjects with daily sodium intake&#xD;
      exceeding 12 grams and was negligible in those with lower sodium intake. Thus, treatment with&#xD;
      paricalcitol appears to be effective in particular in those patients who do not appreciably&#xD;
      benefit of renin angiotensin system (RAS) inhibitors therapy because of high salt intake.&#xD;
      Thus, whether the antiproteinuric effect of paricalcitol is modified by concomitant salt&#xD;
      intake in patients with chronic kidney disease (CKD) on background RAS inhibitors therapy, is&#xD;
      worth investigating.&#xD;
&#xD;
      The broad aim of this study is to evaluate the interaction between paricalcitol therapy and&#xD;
      sodium intake in type 2 diabetes patients with proteinuric kidney disease on stable&#xD;
      background RAS inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in urinary albumin excretion from baseline at 4 month.</measure>
    <time_frame>At baseline and 1,2,3 and 4 month.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory and 24-hour blood pressure profile.</measure>
    <time_frame>At 1 month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory and 24-hour blood pressure profile.</measure>
    <time_frame>At 2 month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory and 24-hour blood pressure profile.</measure>
    <time_frame>At 3 month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory and 24-hour blood pressure profile.</measure>
    <time_frame>At 4 month.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>1-month Paricalcitol 2mcg/day</description>
    <arm_group_label>Paricalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1-month Placebo Treatment</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients;&#xD;
&#xD;
          -  Age &gt; 18 years;&#xD;
&#xD;
          -  Type 2 diabetes patients on low or high sodium diet and stable RAS inhibitor therapy&#xD;
             with the following conditions:&#xD;
&#xD;
        Urinary albumin excretion (UAE) rate &gt;300mg/24 hours (200 mcg/min); Serum creatinine &lt;2&#xD;
        mg/dL, PTH ≥ 20 mEq/L and &lt;110 mEq/L; Calcium and phosphorus levels &lt; 9.5 mg/dl and &lt;&#xD;
        5mg/dl, respectively; Controlled BP (systolic/diastolic &lt;140/90 mmHg) while on stable RAS&#xD;
        inhibitor therapy;&#xD;
&#xD;
        - Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous Vitamin D or Vitamin D analogs therapy (within 3 months prior to the study&#xD;
             entry);&#xD;
&#xD;
          -  Evidence of toxicity to Vitamin D;&#xD;
&#xD;
          -  History of kidney stones;&#xD;
&#xD;
          -  Poorly controlled Diabetes: Hb1Ac &gt; 12%;&#xD;
&#xD;
          -  Therapy with calcitonin, bisphosphonates, cinacalcet, glucocorticoids,&#xD;
             immunosuppressive drugs or other drug that may affect calcium or bone metabolism;&#xD;
&#xD;
          -  Cancer and any severe systemic disease or clinical condition that may jeopardize data&#xD;
             interpretation or completion of the study;&#xD;
&#xD;
          -  Any clinically relevant conditions that might affect study participation and/or study&#xD;
             results;&#xD;
&#xD;
          -  Any contraindication to be exposed to Paricalcitol;&#xD;
&#xD;
          -  Pregnancy or lactating;&#xD;
&#xD;
          -  Women of childbearing potential without following a scientifically accepted form of&#xD;
             contraception;&#xD;
&#xD;
          -  Legal incapacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ASL of Ponte San Pietro - Diabetologic Unit</name>
      <address>
        <city>Brembate</city>
        <state>Bergamo</state>
        <zip>24030</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center fo Rare Diseases Aldo and Cele Daccò</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases</name>
      <address>
        <city>Romano di Lombardia</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bolognini - Unità di Medicina</name>
      <address>
        <city>Seriate</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Paricalcitol</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Sodium intake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

